Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | PDE6D | O43924 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979238 | 0.99 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1740204 | 0.99 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1741831 | 0.98 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2684323 | 0.98 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Tert-Butylamine SCHEMBL1739621 | 0.96 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3885922 | 0.94 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3884325 | 0.93 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL6789988 | 0.90 | HMGCR (0.59) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3971716 | 0.89 | HMGCR (0.58) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16401135 | 0.86 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626093-B2 | Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium | MOREPEN LOBORATORIES LIMITED (IN) | 2020-04-21 | — | — | US | claimed |
| US-20190127334-A1 | NEW POLYMORPHIC FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM & NOVEL PROCESSES FOR CRYSTALLINE AS WELL AS AMORPHOUS ROSUVASTATIN CALCIUM | MOREPEN LABORATORIES LIMITED (IN) | 2019-05-02 | — | — | US | claimed |
| EP-3022213-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LTD (IN) | 2017-06-21 | — | — | EP | claimed |
| US-9518028-B2 | Process for the preparation of Rosuvastatin calcium and preparation of its novel intermediates | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-12-13 | — | — | US | claimed |
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| EP-3022213-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | Suven Life Sciences Limited (IN) | 2016-05-25 | — | — | EP | claimed |
| WO-2015008294-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-01-22 | — | — | WO | claimed |
| EP-3445751-B9 | NEW POLYMORPHIC FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM&NOVEL PROCESSES FOR CRYSTALLINE AS WELL AS AMORPHOUS ROSUVASTATIN CALCIUM | MOREPEN LABORATORIES LTD (IN) | 2023-07-26 | — | — | EP | disclosed |
| EP-3445751-B1 | NEW POLYMORPHIC FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM&NOVEL PROCESSES FOR CRYSTALLINE AS WELL AS AMORPHOUS ROSUVASTATIN CALCIUM | MOREPEN LABORATORIES LTD (IN) | 2023-04-26 | — | — | EP | disclosed |
| US-10626093-B2 | Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium | MOREPEN LOBORATORIES LIMITED (IN) | 2020-04-21 | — | — | US | disclosed |
| US-20190127334-A1 | NEW POLYMORPHIC FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM & NOVEL PROCESSES FOR CRYSTALLINE AS WELL AS AMORPHOUS ROSUVASTATIN CALCIUM | MOREPEN LABORATORIES LIMITED (IN) | 2019-05-02 | — | — | US | disclosed |
| EP-3022213-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LTD (IN) | 2017-06-21 | — | — | EP | disclosed |
| US-9518028-B2 | Process for the preparation of Rosuvastatin calcium and preparation of its novel intermediates | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-12-13 | — | — | US | disclosed |
| US-8507513-B2 | Process for the preparation of rosuvastatin salts | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2013-08-13 | — | — | US | disclosed |
| US-20120116082-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2012-05-10 | — | — | US | disclosed |
| EP-2389365-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | Egis Gyógyszergyár Nyilvánosan Müködö (HU) | 2011-11-30 | — | — | EP | disclosed |
| US-8040819-B2 | Discovery and identification of upstream device characteristics for self-configuration of customer premises equipment | CISCO TECHNOLOGY, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010082072-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | EGIS GYÓGYSZERGYÁR (HU) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009128091-A2 | CRYSTALLINE FORM OF(7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N- METHYL-N-METHYLSULFONYLAMINO)PYRIMIDIN-5-YL]-(3R,5S)- DIHYDROXY-(E)-6-HEPTENOIC ACID INTERMEDIATE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | MATRIX LABORATORIES LIMITED (IN) | 2009-10-22 | — | — | WO | disclosed |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | ORAI1, RYR1, CACNA1E | HMGCR 4/4885ALDH1A1 1749/4885CYP3A4 141/4885 |
| US-20190127334-A1 | NEW POLYMORPHIC FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM & NOVEL PROCESSES FOR CRYSTALLINE AS WELL AS AMORPHOUS ROSUVASTATIN CALCIUM | CACYBP, RAPGEF4, RYR1 | HMGCR 129/4885ALDH1A1 4565/4885CYP3A4 764/4885 |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | HMGCR, PCSK9, CYP4A11 | HMGCR 1/4885ALDH1A1 2138/4885CYP3A4 9/4885 |
| US-10626093-B2 | Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium | CACYBP, ATG4A, RYR1 | HMGCR 59/4885ALDH1A1 4630/4885CYP3A4 493/4885 |
| US-20120116082-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | TERT, SLC30A6, HMGCR | HMGCR 3/4885ALDH1A1 2602/4885CYP3A4 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.